Back to search

Article

Three months of weekly rifapentine and isoniazid versus four months of rifampicin for tuberculosis infection: a randomised controlled trial

2025-08-21

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Treatment of tuberculosis infection (TBI) is a cornerstone of the WHO End TB Strategy. Two widely recommended short-course regimens—weekly isoniazid plus rifapentine for 12 weeks (3HP) and daily rifampicin for 16 weeks (4RIF)—have not been directly compared in a randomised trial. This study aimed to compare treatment completion between 3HP and 4RIF among individuals with TBI....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
875fd84d-2981-57df-b8aa-f146fdc7bcb7
DOI
10.1101/2025.08.18.25330309
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Three months of weekly rifapentine and isoniazid versus four months of rifampicin for tuberculosis infection: a randomised controlled trialDOI 10.1101/2025.08.18.25330309
Outcomes of the three-month weekly isoniazid with rifapentine (3HP) versus the six-month isoniazid preventive therapy (6H) among people newly enrolled in HIV care in western KenyaSemantic proximity
Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in UgandaSemantic proximity
High initiation but sub-optimal completion of tuberculosis preventive treatment among people living with HIV on ART, persistent tuberculosis incidence and programmatic implications: Findings from a two-year multi-country cohort studySemantic proximity
Protocol for a phase 2, partially-blinded, randomised trial assessing the safety and efficacy of sorfequiline or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009)Semantic proximity
Increased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: A retrospective review of routinely collected data at six urban public health facilities in UgandaSemantic proximity
Xpert MTB/RIF<sup>®</sup>cycle threshold as a marker of TB disease severity; Implications for TB treatment stratificationSemantic proximity
Digital adherence technologies to improve tuberculosis treatment outcomes: a cluster-randomised superiority trialSemantic proximity
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trialSemantic proximity
Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trialSemantic proximity
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysisSemantic proximity
16S rRNA gene sequencing of stool samples collected from patients with latent tuberculosis infection before, during, and two months after treatment with 3HP or 4RSemantic proximity
Optimizing delivery strategies for 3HP TB preventive treatment in Tanzania: A qualitative study on acceptability of family approach in HIV care and treatment centersSemantic proximity
Select a neighboring publication to make it the new centre.